Martens Rachel Yap 4

What Happened
Rachel Martens Yap, SVP of Partnerships & Corporate Strategy at Lexicon Pharmaceuticals (LXRX), had 67,090 restricted stock units (RSUs) convert to common stock on February 28, 2026. The company withheld 35,826 of those shares to satisfy tax-withholding obligations at an effective per-share withholding value of $1.47, totaling $52,664. Net shares issued to her were 31,264 (67,090 vested - 35,826 withheld). This was an award/vesting event (compensation), not a market purchase or open-market sale.

Key Details

• Transaction date: February 28, 2026; Form 4 filed March 3, 2026 (timely filing indicated).
• Gross shares vested/converted: 67,090 RSUs.
• Shares withheld for taxes: 35,826 shares at $1.47 per share for $52,664.
• Net shares delivered: 31,264 shares.
• Transaction codes: M = exercise/conversion of a derivative (RSU conversion), F = withholding to satisfy tax liability.
• Footnotes: F1 — each RSU converts to one share; F2 — company withheld shares to cover tax withholding; F3 — RSUs vest 1/3 on Feb 28 of each of the three years following the grant year.
• Shares owned after the transaction are not specified in the provided filing excerpt.

Context
This was a routine equity compensation vesting event (not a buy or an open-market sale). The withholding of shares is a common "sell-to-cover" mechanism to satisfy tax obligations and does not imply a market sale by the insider. For retail investors, purchases or open-market sales by insiders tend to be more informative about sentiment; RSU vesting is primarily compensation-related.